Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vasocardea Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is assigned to 1 distinct examiner and is located within a distinct art unit, indicating a focused prosecution effort for the company's current patent applications. This narrow scope suggests a specific focus on a biotechnological or pharmaceutical innovation. The concentration of the workload under this examiner means that the company's immediate patenting goals are tied to a specific technical review process.
The busiest examiner for the portfolio is TOWNSLEY, SARA ELIZABETH, who holds the pending office action. This matter represents the total pending volume for the company at the USPTO. The immediate outcome for the portfolio is therefore dependent on the specific review and requirements of this examiner within the biotechnology sector. To advance the 1 pending office action, practitioners must navigate the examiner's specific standards while ensuring the company's pharmaceutical innovations meet the requirements of the involved art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18645159 | ANTAGONISTS OF GPR39 PROTEIN | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18645159 | ANTAGONISTS OF GPR39 PROTEIN | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18645159 | ANTAGONISTS OF GPR39 PROTEIN | TOWNSLEY, SARA ELIZABETH | 1629 | §103§112DP | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVasocardea Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Townsley has the most, with 1 of Vasocardea Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
